Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1147 ARTÍCULOS , VIENDO DEL 1126 AL 1140

CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease

Reesink FE, Lemstra AW, van Dijk KD, Berendse HW, van de Berg WD, Klein M, Blankenstein MA, Scheltens P, Verbeek MM, van der Flier WM.

J Alzheimers Dis. 2010;22(1):87-95. doi: 10.3233/JAD-2010-100186.

Neuropathology of dementia with Lewy bodies in advanced age: a comparison with Alzheimer disease

Ubhi K, Peng K, Lessig S, Estrella J, Adame A, Galasko D, Salmon DP, Hansen LA, Kawas CH, Masliah E.

Neurosci Lett. 2010 Nov 26;485(3):222-7. doi: 10.1016/j.neulet.2010.09.016. Epub 2010 Sep 21.

Biomarkers for the early stages of clinical development in Alzheimer's disease

Bordet R, Dartigues JF, Dubois B, Goehrs JM, Vernoux L, Semah F, Pasquier F, Bidaut-Mazel C; participatnts of Round Table n°3 if Giens XXV.

Therapie. 2010 Jul-Aug;65(4):285-90, 277-283. doi: 10.2515/therapie/2010040. Epub 2010 Sep 21.

[Surrogate marker for ABeta42]

Okochi M, Tagami S, Yanagida K, Takeda M.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2010 Aug;30(4):169-72.

Correlation between cognitive impairment and CSF biomarkers in amnesic MCI, non-amnesic MCI, and Alzheimer's disease

Haldenwanger A, Eling P, Kastrup A, Hildebrandt H.

J Alzheimers Dis. 2010;22(3):971-80. doi: 10.3233/JAD-2010-101203.

Plasma cystatin C and risk of developing Alzheimer's disease in subjects with mild cognitive impairment

Ghidoni R, Benussi L, Glionna M, Desenzani S, Albertini V, Levy E, Emanuele E, Binetti G.

J Alzheimers Dis. 2010;22(3):985-91. doi: 10.3233/JAD-2010-101095.

HPA axis dysregulation associated to apolipoprotein E4 genotype in Alzheimer's disease

Gil-Bea FJ, Aisa B, Solomon A, Solas M, del Carmen Mugueta M, Winblad B, Kivipelto M, Cedazo-Mínguez A, Ramírez MJ.

J Alzheimers Dis. 2010;22(3):829-38. doi: 10.3233/JAD-2010-100663.

CSF levels of the histamine metabolite tele-methylhistamine are only slightly decreased in Alzheimer's disease

Motawaj M, Peoc'h K, Callebert J, Arrang JM.

J Alzheimers Dis. 2010;22(3):861-71. doi: 10.3233/JAD-2010-100381.

A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer's disease in a memory clinic

Morinaga A, Ono K, Ikeda T, Ikeda Y, Shima K, Noguchi-Shinohara M, Samuraki M, Yanase D, Yoshita M, Iwasa K, Mastunari I, Yamada M.

Dement Geriatr Cogn Disord. 2010;30(4):285-92. doi: 10.1159/000320265. Epub 2010 Sep 22.

Atypical case of Alzheimer's disease mimicking Creutzfeldt-Jakob disease: interest of cerebrospinal fluid biomarkers in the differential diagnosis

Mahmoudi R, Manckoundia P, Morrone I, Lang PO, Dramé M, Novella JL.

J Am Geriatr Soc. 2010 Sep;58(9):1821-3. doi: 10.1111/j.1532-5415.2010.03051.x.

[Early diagnosis of Alzheimer's disease: the prodromal and preclinical phase]

Valls-Pedret C, Molinuevo JL, Rami L.

Rev Neurol. 2010 Oct 16;51(8):471-80.

Biomarkers for early detection of Alzheimer disease

Barber RC.

J Am Osteopath Assoc. 2010 Sep;110(9 Suppl 8):S10-5.

Cerebrospinal fluid biomarkers in Alzheimer's disease: are the hypotheses more dynamic than the biomarkers?

Spies PE, Verbeek MM, Olde Rikkert MG, Claassen JA.

J Am Geriatr Soc. 2010 Aug;58(8):1619-20. doi: 10.1111/j.1532-5415.2010.03001.x.

Epigenetic modification is linked to Alzheimer's disease: is it a maker or a marker?

Lee J, Ryu H.

BMB Rep. 2010 Oct;43(10):649-55. doi: 10.5483/BMBRep.2010.43.10.649.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias